243 related articles for article (PubMed ID: 19581933)
1. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
Gualberto A; Pollak M
Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.
Gualberto A; Pollak M
Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769
[TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
4. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P
Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288
[TBL] [Abstract][Full Text] [Related]
5. Figitumumab (CP-751,871) for cancer therapy.
Gualberto A
Expert Opin Biol Ther; 2010 Apr; 10(4):575-85. PubMed ID: 20175655
[TBL] [Abstract][Full Text] [Related]
6. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
8. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
Gao J; Chang YS; Jallal B; Viner J
Cancer Res; 2012 Jan; 72(1):3-12. PubMed ID: 22215692
[TBL] [Abstract][Full Text] [Related]
9. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
Yap TA; Olmos D; Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
[TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
[TBL] [Abstract][Full Text] [Related]
12. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
Hofmann F; García-Echeverría C
Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
15. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
Zha J; Lackner MR
Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
[TBL] [Abstract][Full Text] [Related]
16. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
[TBL] [Abstract][Full Text] [Related]
17. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.
Pollak M
Clin Cancer Res; 2012 Jan; 18(1):40-50. PubMed ID: 22215905
[TBL] [Abstract][Full Text] [Related]
18. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
19. [Targeting insulin-like growth factors in the treatment of cancer].
Moro-Sibilot D; Coudurier M; Lantuejoul S
Rev Mal Respir; 2010 Oct; 27(8):959-63. PubMed ID: 20965410
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]